Novo Nordisk already has a collaboration agreement with Catalent, under which it uses these three sites to support the manufacturing of its treatments. The acquisition of these facilities will complement the ongoing significant investments by Novo Nordisk in active pharmaceutical ingredients facilities, and the sites will provide strategic flexibility to the existing supply network.